October 2, 2018
Alnylam Pharmaceuticals said on September 28 that it has submitted a new drug application in Japan for its RNAi therapeutic patisiran for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis. The submission, dated September 27, comes after the drug’s approval in...read more